Camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy in women with recurrent or metastatic cervical cancer

被引：1
|
作者：
Wu, X. [1 ]
Xia, L. [1 ]
Zhang, K.
Tang, Y. [2 ]
Zhang, G. N. [3 ]
Wang, D. [4 ]
Lou, H. [5 ]
Liu, N. [6 ]
Zhang, H. [7 ,8 ,16 ]
Chen, H. [9 ]
Wang, K. [10 ]
Wei, S. [11 ]
Wang, L. [12 ,13 ]
Gao, K. [14 ]
Li, G. [15 ]
Zhang, H. [7 ,8 ,16 ]
Hu, Y. [17 ]
Zhou, X. [18 ]
Wang, Y. [18 ]
Wang, Q. [18 ]
机构：
[1] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Gynecol Oncol,Xiangya Sch Med, Changsha, Peoples R China
[3] Univ Elect Sci Technol China, Sch Med, Sichuan Canc Hosp Inst, Dept Gynecol Oncol, Chengdu, Peoples R China
[4] Liaoning Canc Hosp & Inst, Dept Gynecol, Shenyang, Peoples R China
[5] Zhejiang Canc Hosp, Dept Gynecol Surg, Hangzhou, Peoples R China
[6] Shandong Canc Hosp & Inst, Dept Gynecol Oncol, Jinan, Peoples R China
[7] Kunming Med Univ, Dept Gynecol Oncol, Yunnan Canc Hosp, Kunming, Peoples R China
[8] Kunming Med Univ, Affliated Hosp 3, Kunming, Yunnan, Peoples R China
[9] Xi An Jiao Tong Univ, Dept Radiat Oncol, Affiliated Hosp 1, Xian, Peoples R China
[10] Tianjin Med Univ Canc Inst & Hosp, Dept Gynecol Oncol, Tianjin, Peoples R China
[11] Shanxi Canc Hosp, Comprehens Internal Med, Taiyuan, Peoples R China
[12] Zhengzhou Univ, Dept Gynecol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[13] Henan Canc Hosp, Zhengzhou, Peoples R China
[14] Guangxi Med Univ Canc Hosp, Gynecol Oncol, Nanning, Peoples R China
[15] Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Ctr Union Hosp, Dept Gynecol Oncol, Wuhan, Peoples R China
[16] Hubei Canc Hosp, Dept Gynecol Oncol, Wuhan, Peoples R China
[17] Tianjin Cent Hosp Gynecol Obstet, Dept Gynecol Oncol, Tianjin, Peoples R China
[18] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA44
引用
收藏
页码：S1284 / S1285
页数：2
相关论文
共 50 条
  • [1] A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
    Lingfang Xia
    Qi Zhou
    Yunong Gao
    Wenjing Hu
    Ge Lou
    Hong Sun
    Jianqing Zhu
    Jin Shu
    Xianfeng Zhou
    Rong Sun
    Xiaohua Wu
    [J]. Nature Communications, 13 (1)
  • [2] A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
    Xia, Lingfang
    Zhou, Qi
    Gao, Yunong
    Hu, Wenjing
    Lou, Ge
    Sun, Hong
    Zhu, Jianqing
    Shu, Jin
    Zhou, Xianfeng
    Sun, Rong
    Wu, Xiaohua
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [3] Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer
    Chen, Zhongjie
    Yan, Bo
    Xu, Liming
    Huang, Xin
    Li, Meng
    Wang, Jun
    Zhu, Li
    Yuan, Zhiyong
    Wang, Ping
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.
    Ji, Dongmei
    Shen, Weina
    Kuang, Muyu
    Liu, Ying
    Li, Huajun
    Wang, Yu
    Ji, Qinghai
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma
    Gong, Jinhong
    Shang, Jingjing
    Su, Dan
    Qian, Xiaodan
    Liu, Guangjun
    Sun, Zhiqiang
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 709 - 717
  • [6] Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.
    Chen, Ming-Yuan
    Chen, Xiaozhong
    Zhang, Ximei
    Liu, Tianshu
    Wang, Xicheng
    Cai, Jinling
    Wang, Shuni
    Chen, Chunxia
    Fan, Jia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18031 - E18031
  • [7] Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
    Ding, Xi
    Hua, Yi-Jun
    Zou, Xiong
    Chen, Xiao-Zhong
    Zhang, Xi-Mei
    Xu, Bei
    Ouyang, Yan-Feng
    Tu, Zi-Wei
    Li, Hui-Feng
    Duan, Chong-Yang
    Zhang, Wei-Jing
    You, Rui
    Liu, You-Ping
    Liu, Yong-Long
    Yang, Qi
    Huang, Pei-Yu
    Wang, Shu-Ni
    Fan, Jia
    Chen, Ming-Yuan
    [J]. ECLINICALMEDICINE, 2023, 61
  • [8] Bevacizumab plus chemotherapy versus combination chemotherapy only in metastatic, recurrent, and persistent cervical cancer
    Choi, H.
    Kim, B. G.
    Lee, Y. Y.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 275 - 275
  • [9] Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study
    Xia, L.
    Zhou, Q.
    Zhang, Y.
    Gao, Y.
    Hu, W.
    Pan, M.
    Lou, G.
    Wang, L.
    Shi, H.
    Zhu, J.
    Sun, H.
    Wang, X.
    Wang, Q.
    Wu, X.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S630 - S630
  • [10] PHASE 3 RECURRENT/METASTATIC CERVICAL CARCINOMA TRIAL: SUBGROUP EFFICACY ANALYSIS OF CEMIPLIMAB VERSUS INDIVIDUAL INVESTIGATOR'S CHOICE CHEMOTHERAPY
    Lorusso, D.
    Vergote, I.
    Oaknin, A.
    Tewari, K. S.
    De Melo, A. C.
    Kim, H. S.
    Kim, Y. M.
    Lisyanskaya, A.
    Damian, F.
    Chang, C. L.
    Rischin, D.
    Takahashi, S.
    Ramone, D.
    Pikiel, J.
    Guerra Alia, E. M.
    Li, J.
    Jamil, S.
    Mathias, M.
    Fury, M. G.
    Monk, B. J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A10 - A11
12345